SOHO Italy 1st School of Multiple Myeloma

 

Videos
20:07

SOHO Italy 1st School of Multiple Myeloma

Present Landscape of R/R MM: Post-Bortezomib, Post-Lenalidomide

FEATURING Claudio Cerchione
  • 201 views
  • July 7, 2021
  • 1
09:45

SOHO Italy 1st School of Multiple Myeloma

Near-Future Therapy Landscape of R/R MM at Second or Subsequent Relapse

FEATURING Claudio Cerchione
  • 132 views
  • July 7, 2021
  • 1
30:19

SOHO Italy 1st School of Multiple Myeloma

[PRIVATE] Present & Near Future of R/R MM: Post-Bortezomib, Post-Lenalidomide, Selinexor, BCMA-Targeted IO, Belantamab Mafodotin

FEATURING Claudio Cerchione
  • 234 views
  • February 9, 2021
  • 3
13:49

SOHO Italy 1st School of Multiple Myeloma

MM & Extracellular Vesicles: Do MICA+ EVs Impair NKG2D-Mediated NK Cell Immunesurveillance?

FEATURING Elisabetta Vulpis
  • 13 views
  • February 9, 2021
27:26

SOHO Italy 1st School of Multiple Myeloma

Cell-Adhesion System Targeting in MM: How Does JAM-A Expression Correlate With Disease Outcomes? Can We Block Angiogenesis and Impair Disease Progression and Dissemination?

FEATURING Antonio Solimando
  • 5 views
  • February 5, 2021
22:20

SOHO Italy 1st School of Multiple Myeloma

Single-Cell Characterization of the BM Immune Microenvironment in MM: Genomics of SMM, MGUS to Myeloma, CD27-T-Cells as Source of Tumor-Reactive Lymphocytes, Immune-Cell Subsets, Neo-Antigens

FEATURING Cirino Botta
  • 27 views
  • February 5, 2021
23:39

SOHO Italy 1st School of Multiple Myeloma

ASCT in MM in Novel Agents Era: Is Long-Term Disease Control and Survival Attainable in Relapsing/Progressing After Allo-SCT?

FEATURING Attilio Olivieri
  • 10 views
  • February 5, 2021
16:03

SOHO Italy 1st School of Multiple Myeloma

Primary Plasma Cell Leukemia Peru Experience: How Common Is PCL in MM Patients? What Is the Correlation of OS and SCT?

FEATURING Jule Vasquez
  • 24 views
  • February 5, 2021
19:12

SOHO Italy 1st School of Multiple Myeloma

1st/2nd Relapse in MM: Predictive Factors, EMD, Role of sFLC in MGUS/SMM/MM, Bortezomib/Lenalidomide Treatment

FEATURING Uros Markovic
  • 10 views
  • February 5, 2021
16:38

SOHO Italy 1st School of Multiple Myeloma

Extracellular Vesicles in Myeloma: What Is Their Role in MGUS-to-MM Evolution and Progression?

FEATURING Antonia Reale
  • 10 views
  • February 5, 2021
13:44

SOHO Italy 1st School of Multiple Myeloma

MRD Assessment Within the Bone Marrow of MM: Immunoglobulin Genes as Markers for MRD, CD3 Stability, Clonotype Assessment, NGS, Liquid Biopsy

FEATURING Carolina Terragna
  • 68 views
  • February 5, 2021
  • 2
22:16

SOHO Italy 1st School of Multiple Myeloma

Molecular Pathogenesis of MM: MGUS and SMM, Genomic Complexity of the Disease, APOBEC Activity, Cytogenetic Events

FEATURING Niccolo Bolli
  • 190 views
  • February 5, 2021
  • 3
18:23

SOHO Italy 1st School of Multiple Myeloma

Bone Marrow Fibroblasts in MM Progression and Tumor Cells Reprogramming: What Role Does It Play in Enhancing Cell Proliferation and Reducing Bortezomib-Induced Apoptosis?

FEATURING Ilaria Saltarella
  • 2 views
  • February 4, 2021
20:55

SOHO Italy 1st School of Multiple Myeloma

The Myeloma-Specific Tumor Suppressor FAM46C: How Does It Work & What Are the Perspectives?

FEATURING Enrico Milan
  • 3 views
  • February 4, 2021
08:20

SOHO Italy 1st School of Multiple Myeloma

1L LenDex Combo in Frail MM Patients: How Effective Is It? Is There a Benefit of Continuous Therapy?

FEATURING Claudia Bellofiore
  • 3 views
  • February 4, 2021
13:41

SOHO Italy 1st School of Multiple Myeloma

NGS in ALL: Is INO Effective in MRD+ Patients Before HSCT? How Valuable Is Genetic Profiling?

FEATURING Giovanni Martinelli
  • 171 views
  • February 4, 2021
  • 1
16:57

SOHO Italy 1st School of Multiple Myeloma

Anti-CD38 in MM Daily Practice: How Can We Potentiate the Action of Daratumumab?

FEATURING Claudio Cerchione
  • 88 views
  • February 4, 2021
  • 1
26:05

SOHO Italy 1st School of Multiple Myeloma

Introducing Anti-CD38 in Daily Practice of MM: Updates on the GRIFFIN and MAIA trials

FEATURING Claudio Cerchione
  • 89 views
  • February 4, 2021
  • 1
19:13

SOHO Italy 1st School of Multiple Myeloma

Daratumumab in MM Daily Practice: Is It Becoming the New Backbone?

FEATURING Claudio Cerchione
  • 90 views
  • February 4, 2021
  • 1
10:00

SOHO Italy 1st School of Multiple Myeloma

Bone Marrow CD8+ Tissue-Resident Memory T-Cells in MM: Can the Increase of CD8+ TRM Cells With a CM Phenotype Have an Anti-Tumor Role in the Disease Control?

FEATURING Melania Carlisi
  • 3 views
  • February 4, 2021
13:19

SOHO Italy 1st School of Multiple Myeloma

European Experience in MM: What Are the Potential 1L Options for Transplant-(In)Eligible Pts? KdD vs Kd, Isa-Kd vs Kd, PVd, SVd - What Is the Best Choice for R/R Disease?

FEATURING Maria-Victoria Mateos
  • 13 views
  • February 3, 2021
10:48

SOHO Italy 1st School of Multiple Myeloma

Exploring Microenvironment of Multiple Myeloma: How Important Is It in Treatment Decision-Making?

FEATURING Alessandra Romano
  • 9 views
  • February 3, 2021
09:25

SOHO Italy 1st School of Multiple Myeloma

2021 Update Combination Therapies in R/R MM: Which Options Are the Most Effective? What Is the Impact of Early Relapse Following Induction With Novel Agents?

FEATURING Francesca Fazio
  • 9 views
  • February 3, 2021
15:22

SOHO Italy 1st School of Multiple Myeloma

Dissecting Daratumumab Mechanisms of Resistance in MM: Identification of New Biomarkers Able to Predict Possible Treatment Failure

FEATURING Matteo Claudio Da Via
  • 123 views
  • February 3, 2021
  • 1
09:34

SOHO Italy 1st School of Multiple Myeloma

Comparison of Different Imaging Techniques in MM: Whole-Body Computed Tomography vs. Conventional Skeletal Survey

FEATURING Sara Grammatico
  • 9 views
  • February 3, 2021
10:25

SOHO Italy 1st School of Multiple Myeloma

Combination Therapy in MM: Does Doxorubicin & ENPP1 Inhibitor Combination Improve Anti-Myeloma Innate Immune Response?

FEATURING Lorenzo Cuollo
  • 15 views
  • February 3, 2021
11:33

SOHO Italy 1st School of Multiple Myeloma

Allograft in MM: Is There a Role for AlloHSCT & Will Newer Drug Therapies Reduce Its Use?

FEATURING Federico Vozella
  • 2 views
  • February 3, 2021
14:02

SOHO Italy 1st School of Multiple Myeloma

2021 Update on R/R MM: Does the Addition of BCNU to Melphalan Improve Survival Before Second ASCT?

FEATURING Joshua Thomas
  • 19 views
  • February 3, 2021